This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 0IVZ
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Competidores de Global Blood Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.48 |
| 52 Week High | US$72.00 |
| 52 Week Low | US$21.75 |
| Beta | 0.46 |
| 1 Month Change | 0.94% |
| 3 Month Change | 126.38% |
| 1 Year Change | 163.74% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 13.85% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 0IVZ | GB Biotechs | Mercado GB | |
|---|---|---|---|
| 7D | 0.9% | 5.9% | 1.0% |
| 1Y | 163.7% | -26.7% | 3.0% |
Rentabilidad vs. Industria: 0IVZ exceeded the UK Biotechs industry which returned -38.4% over the past year.
Rentabilidad vs. Mercado: 0IVZ exceeded the UK Market which returned -12.6% over the past year.
Volatilidad de los precios
| 0IVZ volatility | |
|---|---|
| 0IVZ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Precio estable de las acciones: 0IVZ's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine 0IVZ's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2011 | 457 | Ted Love | www.gbt.com |
Resumen de fundamentos de Global Blood Therapeutics, Inc.
| Estadísticas fundamentales de 0IVZ | |
|---|---|
| Capitalización bursátil | US$4.62b |
| Beneficios(TTM) | -US$322.46m |
| Ingresos (TTM) | US$234.86m |
19.7x
Ratio precio-ventas (PS)-14.3x
Ratio precio-beneficio (PE)¿Está 0IVZ sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 0IVZ | |
|---|---|
| Ingresos | US$234.86m |
| Coste de los ingresos | US$4.45m |
| Beneficio bruto | US$230.41m |
| Otros gastos | US$552.87m |
| Beneficios | -US$322.46m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -4.78 |
| Margen bruto | 98.10% |
| Margen de beneficio neto | -137.30% |
| Ratio deuda/patrimonio | 491.7% |
¿Cómo se ha desempeñado 0IVZ a largo plazo?
Ver rendimiento histórico y comparativa